PT - JOURNAL ARTICLE AU - Schmid, Jonas Andreas AU - Festl, Yasmin AU - Severin, Yannik AU - Bacher, Ulrike AU - Kronig, Marie-Noëlle AU - Snijder, Berend AU - Pabst, Thomas TI - Efficacy and feasibility of Pharmacoscopy-guided treatment for acute myeloid leukemia patients that exhausted all registered therapeutic options AID - 10.1101/2023.03.28.23287745 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.28.23287745 4099 - http://medrxiv.org/content/early/2023/03/29/2023.03.28.23287745.short 4100 - http://medrxiv.org/content/early/2023/03/29/2023.03.28.23287745.full AB - Elderly or unfit patients with relapsed acute myeloid leukemia (AML) face a poor prognosis and are likely to rapidly exhaust all registered treatment options. Pharmacoscopy, an image-based ex vivo drug screening platform, has previously been suggested as a tool for treatment selection in AML. We used pharmacoscopy to generate personalized treatment recommendations for 30 relapse settings of 24 AML patients which exhausted all standard therapeutic options. We evaluated whether pharmacoscopy can be employed within the narrow timeframe available under an AML relapse setting, how often recommended regimens could be started and whether they provided durable clinical benefits. 17 of 30 screens (56.7%) resulted in patients receiving a recommended therapy, leading to promising trends in clinical response and survival. A drug regimen’s integrated pharmacoscopy score proved to be an excellent predictor of clinical response: Patients receiving a regimen with above-median scores showed significantly higher rates of complete remission (OR 3.01, p < 0.0005) and significantly longer overall survival (ratio 3.39, p < 0.006). We conclude that pharmacoscopy is an efficient and valuable tool for therapy selection in AML at relapse and propose concrete measures to further improve clinical implementation.Competing Interest StatementB.S. was a scientific co-founder of Allcyte GmbH, which has been acquired by Exscientia. B.S. is a shareholder of Exscientia and a co-inventor on U.S. patent application 15/514,045 relevant to the study. B.S. declares research funding from Roche and speaker fees from Novartis, GSK, and AbbVie. All other authors declare no potential conflicts of interest.Clinical TrialNCT05732688Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol predefined and approved by the Swiss Kantonal Ethical Committee (KEK, DARTT-1; BASEC-ID: 2021-01294). The study is registered at clinicaltrials.gov (NCT05732688).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data required to reproduce our results are included in the tables and supplementary tables. Additional data generated in this study are not publicly available due to information that could compromise patient privacy or consent but are available upon reasonable request from the corresponding author.